Overview

A Study to Test the Long-term Safety, Tolerability and Efficacy of Brivaracetam in Study Participants 2 to 26 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy

Status:
Not yet recruiting

Trial end date:
2026-07-01

Target enrollment:

Participant gender:

Summary

The purpose of the study is to investigate the long-term safety, tolerability and efficacy of brivaracetam in pediatric study participants with childhood absence epilepsy (CAE) or juvenile absence epilepsy (JAE).

Phase:

Phase 3

Details

Lead Sponsor:

UCB Biopharma SRL

Treatments:

Brivaracetam